Catégorie : Biotech

OSE IMMUNOTHERAPEUTICS

by jbertholdin Biotech, Pharma

OSE IMMUNOTHERAPEUTICS

About the company

OSE Immunotherapeutics is an integrated Clinical Stage biotech company mastering complex biology with regards to T-cells and myeloid cells, focused on developing first-in-class assets targeting immuno-oncology, Autoimmune and inflammatory diseases.

About the solution

OSE Immunotherapeutics has a dynamic partnership business model based on innovative products that generates non-dilutive revenues and finances R&D programs. These products have real blockbuster potential and give to OSE-Immunotherapeutics, an ability to conclude global agreements at different stages of their development with major pharmaceuticals players. We are interested to discuss potential collaborations. OSE-Immunotherapeutics actively seeks international partners for out-Licencing of compounds at all stages of clinical development of drug products.

Website
Key information

–  Therapeutic areas: Immuno-oncology, Autoimmune diseases, Inflammatory diseases

–  Based in: Headquarter : Nantes (FRANCE) Offices : Paris (FRANCE)

–  Employees: 51 – 200

–  Created in: 2012

SURGE CARE

by jbertholdin Biotech, Pharma

SURGE CARE

About the company

Founded with the goal of revolutionizing precision medicine, Surge is an innovative company specializing in in-depth understanding of the immune system using AI. Thanks to significant technological advancements and a team of top-notch researchers coming from the US and from France, Surge is committed to creating innovative solutions to pave the way for personalized medicine of tomorrow. With the launch of its first product, PreCyte®, for predicting the risk of postoperative complications, and its premier laboratory, SurgeLab™, for acquiring individualized immune signatures, the company aims to become a leader in precision immune analysis.

About the solution

SurgeCare develops two main products :
– SurgeLab™, a lab platform focused on acquiring immune signatures, and
– PreCyte®, a range of medical devices for precision medicine.

Founded in 2021 with innovative technology for identifying predictive immune biomarkers, Surge, from 2021 to 2023, developed a first prototype to anticipate the risk of post-operative infections in patients undergoing major digestive surgery. A clinical study conducted from 2022 to 2023 revealed that their prototype outperforms existing methods by more than three times in terms of predictive capability. In 2024, this prototype enters its final phase of industrialization, with deployment planned as a pilot in the fourth quarter of 2024.

Meanwhile, in response to the growing interest of their partners, they have initiated the opening of their SurgeLab platform, which offers comprehensive immune screening, including ex-vivo blood stimulation, collection of biological parameters via a specialized panel, and data analysis through machine learning, reinforcing their commitment to innovation in precision medicine.

Website
Key information

–  Therapeutic areas: Surgery, Immunology, Precision Medicine

–  Based in: Strasbourg (FRANCE) & Stanford University (StartX) (USA)

–  Employees: 11 – 50

–  Created in: 2021

NEURON EXPERTS

by jbertholdin Biotech, Pharma

NEURON EXPERTS

About the company

Neuron Experts is a private CRO, created in 2008, specialized in cultures of neurons mimicking neurodegenerative diseases. It is located in Marseille, France, where it has 250 m² of independent laboratory. 80% of its turnover is exported.

About the solution

Neuron Experts has developed its own tests based human and rat invitro models reproducing neurodegenerative diseases such as AD, PD, HD, ALS, MS diseases. These models allow to test efficacy of compounds from pharmaceutical and start-up as well as understanding their mode of action in theses pathologies

Website
Key information

–  Therapeutic areas: Neurodegenerative disease, Skin disease

–  Based in: Marseille (FRANCE)

–  Employees: 1-10

–  Created in: 2008

PK MED

by jbertholdin Biotech, Pharma

PK MED

About the company

PK MED is a French innovative biotech company, privately owned and established in 2019 with the support of Truffle Capital, a prominent European Venture Capital firm specializing in Life sciences.

​PK MED specializes in the innovative development of custom-designed, injectable, and biodegradable micro-implants. Their expertise spans across critical healthcare domains, focusing on local drug delivery systems for rheumatology (PKM-01) and enhancing cell-homing techniques to improve bone marrow transplantation outcomes (PKM-02).

About the solution

Lead product candidate PKM-01 is developed to treat gout, an excruciating and increasingly prevalent form of arthritis. Today, approved products take time to partially alleviate pain and come with real safety risks.
PKM-01 is a drug combination product (sustained release formulation of the anti-inflammatory drug, colchicine, and an anesthetic) to be injected in the effected joint. PKM-01 is designed to be a new treatment paradigm in gout flares – a safe and very effective pain killer providing relief within minutes.

Website
Key information

–  Therapeutic areas: Rheumatology, Bone marrow transplantation

–  Based in: Headquarter : Paris (FRANCE) R&D : Lyon (FRANCE)

–  Employees: 1-10

–  Created in: 2019

NICOX

by jbertholdin Biotech, Pharma

NICOX

About the company

Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Their lead program in the ophthalmic pipeline, NCX 470, is currently in Phase 3 clinical development targeting glaucoma. Their ophthalmic pipeline also includes a candidate under preclinical evaluation for development in retinal conditions, NCX 1728, and a clinical-stage product candidate for dry eye disease licensed exclusively to a partner for the Chinese market, NCX 4251.

They have two products commercialized in the U.S.: VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% for open-angle glaucoma and ZERVIATE® (cetirizine ophthalmic solution) 0.24% for ocular allergic conjunctivitis. These products are being rolled out in territories outside of the U.S. through partnerships.

About the solution

NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop targeting glaucoma that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. The first of two Phase 3 trials for NCX 470, Mont Blanc, met the efficacy requirements for approval in the U.S. The similarly designed and ongoing second Phase 3 trial, Denali, conducted at clinical sites in the U.S. and China is ongoing with topline results are expected in H2 2025.

Website
Key information

–  Therapeutic areas: Ophthalmology

–  Based in: Sophia Antipolis (FRANCE), Durham (USA)

–  Employees: 11 – 50

–  Created in: 1996

APMONIA THERAPEUTICS

by jbertholdin Biotech, Pharma

APMONIA THERAPEUTICS

About the company

Apmonia Therapeutics is a biotechnology company dedicated to developing therapeutic strategies towards cancer. They are developing a first-in-class pipeline of next-generation peptide-based therapies targeting the tumor microenvironment to improve the lives of patients with cancer.

Using molecular modeling (i.e., ligand:protein and protein:protein docking simulations, as well as molecular dynamics simulations) and their vast knowledge of matrix biology and oncology, they are developing a portfolio of proprietary first-in-class peptide-based therapies targeting the tumour extracellular matrix (ECM) molecules. After years of research on cancer-stroma interactions, they identified several proteins which are overexpressed in different types of solid tumours, converting them into potential targets for anticancer treatments. By producing peptides that selectively target ECM components, they can regulate the interplay between cancer and stromal cells within the TME, disrupting tumoural activity.

About the solution

Their lead program, AP-01 (or TAX2), is a peptide-based technology targeting tumor-overexpressed thrombospondin-1 (TSP-1) to prevent CD47 receptor activation. AP-01 acts as a modulator of the tumor-tolerant microenvironment, reprogramming highly vascularized tumors into poorly angiogenic ones while concomitantly activating the tumor-inhibiting immune system. Thanks to its unique mode of action, AP-01 does not recapitulate the hematologic toxicities related to CD47 blockade, hence realizing the full potential of targeting this axis for cancer therapy.

A large body of in vivo efficacy data supports the proof-of-concept for AP-01 use as an anti-cancer therapy. TAX2 activates the adaptive (tumor-specific) immune response, as demonstrated by activation of T-cells, production of interferon gamma, and significant tumor reduction. The T cell stimulatory activities of AP-01 also position it as an excellent candidate for combination therapies in the context of a broad immune-oncology approach.

Their current focus for clinical development is ovarian cancer, an orphan indication. They plan to target other indications including glioblastoma, colorectal cancer, and pancreatic cancer.

Website
Key information

–  Therapeutic areas: Oncology

–  Based in: Reims (FRANCE)

–  Employees: 1 – 10

–  Created in: 2019

VECT-HORUS

by jbertholdin Biotech, Pharma

VECT-HORUS

About the company

Vect-Horus is a privately held biotechnology company that designs and develops molecular vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumors. Founded in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), formerly headed by Dr Michel Khrestchatisky, co-founder of the company. Vect-Horus has 40 employees (most in R&D).

By combining pharmaceutical agents to its vectors, VECT-HORUS enables their transport across the BBB, which significantly impedes brain delivery of most drugs. Proof of concept of the technology was demonstrated in animal models for different vectorized molecules (Oligonucleotides, Antibodies, NPs…).

Based on its potential to target specific receptors, notably those that are found at high levels in some pathological tissues, the Company is also targeting cancers (pancreatic, adrenal cancer, glioblastoma, etc.), where there is a high unmet medical need.

About the solution

VECT-HORUS discovered, validated, and optimized different families of molecular vector that target the LDL Receptor, Transferrin Receptor and undisclosed ones that allow drug targeted delivery to different organs.

The vectors are protected by several families of patents and ongoing patent applications. They have different properties (structure, affinity, stability, organ specificity) allowing adaptation of the vectorization process on a case-to-case basis.

Vect-Horus seeks to develop the broad potential of its proprietary VECTrans® technology platform through partnerships and licensing agreements with pharmaceutical and biotechnology companies in multiple therapeutic applications.

Website
Key information

–  Therapeutic areas: Central Nervous System, Neuromuscular, Cardiovascular, Ophtalmological, Oncology, Pulmonary

–  Based in: Marseille (FRANCE)

–  Employees: 11 – 50

–  Created in: 2005

MABQI

by jbertholdin Biotech, Pharma

MABQI

About the company

Mabqi is a high-tech developer of human therapeutic antibodies. Its phage display core technology platform allows the development of functional antibodies (including pH-sensitive antibodies selected from our oncology-dedicated library) with high developability through proprietary synthetic human libraries. Based on the technical expertise built on more than 20 successful discovery programs (Servier, ADC Therapeutics, … ) and the clinical expertise of its Medical Advisory Board, Mabqi is actively building a portfolio of first-in-class and best-in-class proprietary antibodies with high therapeutic potential in oncology.

Some of these assets are already available for partnered development and licensing opportunities. Mabqi provides also customized discovery services, including full antibody characterization, and has developed a unique and dedicated library to select pH-dependent antibodies for oncology indications.

About the solution

Thanks to smooth integration of high throughput discovery processes and AI, Mabqi is able to propose a portfolio of outstanding, readily developable antibodies: Tumor Microenvironment Targeting through pH sensitivity, excellent affinity ranges on membrane proteins and biological functionality are combined to offer solutions even in the most complicated cases.

Website
Key information

–  Therapeutic areas: Oncology, Immune diseases

–  Based in: Montpellier (FRANCE)

–  Employees: 11-50

–  Created in: 2017

ORAKL ONCOLOGY

by jbertholdin Biotech, Digital Health, Pharma

ORAKL ONCOLOGY

About the company

The current drug development process does not capture cancer complexity or heterogeneity. This is a main reason why 96% of drugs fail when they meet patients in clinical trials, lacking efficacy in the patient population.

Orakl Oncology stands at the forefront of the techbio landscape, pioneering the use of patient tumor avatars to meticulously accelerate and de-risk drug development in collaboration with oncology players.


As a spin-out from Gustave Roussy (2023), the 4th cancer center in the world, Orakl’s boasts unique access to a vast repository of patient tissue samples and associated data. This strategic foundation positions them to scale quickly across a vast number of cancer subtypes starting with colorectal and pancreatic cancers.

The founders and team collectively bring unparalleled expertise in cancer cell biology and engineering. With over 30 years of combined academic experience across France, the UK, and the US, they are dedicated to improving cancer treatment. The company has already been funded 5M€ in equity and grants for their first developments.

About the solution

Orakl Oncology is a techbio platform that is building a unique collection of patient tumor avatars, each of them combining the best biology and patient clinical and molecular data. As a spin-out from Gustave Roussy, the 4th cancer center in the world, they are positionned to scale quickly across a vast number of cancer subtypes starting with colorectal and pancreatic cancers. This combination of biology and data, scalable and supported by proprietary know-how, is an extraordinary differenciating factor.


Their cutting-edge approach involves the integration of functional testing and AI-powered analysis to predict patient response to treatments and stratify populations. They already obtained excellent predictive values, at the patient and population levels.


Orakl discovers and develops new drugs that will succeed in the clinic, for their own pipeline or in co-development with oncology companies.

Website
Key information

–  Therapeutic areas: Oncology

–  Based in: Paris (FRANCE)

–  Employees: 1-10

–  Created in: 2023

INFLECTIS BIOSCIENCE

by jbertholdin Biotech, Pharma

INFLECTIS BIOSCIENCE

About the company

InFlectis is a French-based drug discovery company, incoporated in 2013, developing first-in-class therapies for neurological rare diseases. They are in clinical development with an orally available small molecule that has the potential to extend lives or improve the quality-of-life for people suffering from ALS. They are also ready to enter in phase 2 clinical trial in Charcot-Marie-Tooth disease and preclinical proof of efficacy has been obtained in rare cerebellar ataxias.

About the solution

IFB-088 is a first-in-class orally available small molecule drug candidate with a validated mechanism of action and a promising pharmacokinetic profile capable of crossing the blood brain barrier to target the central and peripheral nervous system. IFB-088 is a multifunctional drug that modulates the PPP1R15A/PP1c phosphatase complex and inhibits NR2B-containing NMDAR. The potential of IFB-088 lies in its ability to target different major cellular pathophysiological mechanisms to manage disease progression: protein aggregation, oxidative stress, and glutamate excitotoxicity.

Website
Key information

–  Therapeutic areas: Neurological rare diseases

–  Based in: Nantes (FRANCE)

–  Employees: 1-10

–  Created in: 2013